Pharmacokinetics of tramadol and its three main metabolites in healthy male and female volunteers

Biopharmaceutics and Drug Disposition

Volumn 28, Issue 9, 2007, Pages 527-534

  Ardakani, Yalda H ^a   Rouini, Mohammad Reza ^a  

^a TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

N desmethyltramadol; O,N didesmethyltramadol; O desmethyltramadol; Pharmacokinetics; Tramadol

Indexed keywords

DINORTRAMADOL; DRUG METABOLITE; NORTRAMADOL; TRAMADOL; UNCLASSIFIED DRUG;

ADULT; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG ELIMINATION; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN EXPERIMENT; IRAN; MALE; MAXIMUM PLASMA CONCENTRATION; NORMAL HUMAN; PHENOTYPE; PLASMA HALF LIFE; SEX DIFFERENCE; SINGLE DRUG DOSE; TABLET; TIME TO MAXIMUM PLASMA CONCENTRATION; VOLUNTEER;

ADMINISTRATION, ORAL; ADULT; ANALGESICS, OPIOID; AREA UNDER CURVE; FEMALE; HALF-LIFE; HUMANS; IRAN; MALE; PHENOTYPE; POLYMORPHISM, GENETIC; SEX FACTORS; TRAMADOL;

EID: 38849179383     PISSN: 01422782     EISSN: 1099081X     Source Type: Journal    
DOI: 10.1002/bdd.584     Document Type: Article

References (16)

1. Raffa RB, Friderichs E, Reimann W, Shank RP, Codd EE, Vaught JL. Opioid and nonopioid components independently contribute to the mechanism of action of tramadol, an 'atypical' opioid analgesic. J Pharmacol Exp Ther 1992; 260: 275-285.
2. Scott LJ, Perry CM. Tramadol: a review of its use in perioperative pain. Drugs 2000; 60: 139-176.
3. Gibson TP. Pharmacokinetics, efficacy, and safety of analgesia with a focus on tramadol HCI. Am J Med 1996; 101(1A): 47S-53S.
4. Lintz W, Barth H, Becker R, Frankus E, Schmidt-Bothelt E. Pharmacokinetics of tramadol and bioavailability of enteral tramadol formulations. 2nd communication: drops with ethanol. Arzneimittelforschung 1998; 48: 436-447.
5. Lee CR, McTavish D, Sorkin EM. Tramadol: a preliminary review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in acute and chronic pain states. Drugs 1993; 46: 313-340.
6. Lintz W, Erlacin S, Frankus E. Biotransformation of tramadol in man and animal [in German]. Arzneimittelforschung 1981; 31: 1932-1943.
7. Paar WD, Poche S, Gerloff J, Dengler HJ. Polymorphic CYP2D6 mediates O-demethylation of the opioid analgesic tramadol. Eur J Clin Pharmacol 1997; 53: 235-239.
8. Nobilis M, Kopecky J, Kvetina J. High-performance liquid chromatographic determination of tramadol and its O-desmethylated metabolite in blood plasma: application to a bioequivalence study in humans. J Chromatogr A 2002; 949: 11-22.
9. Hui-Chen L, Yang Y, Na W, Ming D, Jian-Fang L, Hong-Yuan X. Pharmacokinetics of the enantiomers of trans-tramadol and its active metabolite, trans-O-demethyltramadol, in healthy male and female Chinese volunteers. Chirality 2004; 16: 112-118.
10. Rouini MR, Ardakani YH, Soltani F, Aboul-Enein HY, Foroumadi A. Development and validation of a rapid HPLC method for simultaneous determination of tramadol, and its two main metabolites in human plasma. J Chromatogr B Analyt Technol Biomed Life Sci 2006; 830: 207-211.
11. Mahgoub A, Idle JR, Dring LG, Lancaster R, Smith RL. Polymorphic hydroxylation of debrisoquine in man. Lancet 1977; 2: 584-586.
12. Slanar O, Nobilis M, Kvetina J, Matouskova O, Idle JR, Perlik F. Pharmacokinetics of tramadol is affected by MDR1 polymorphism C3435T. Eur J Clin Pharmacol 2007; 63: 419-421.
13. Abdel-Rahman SM, Leeder JS, Wilson JT, et al. Concordance between tramadol and dextromethorphan parent/metabolite ratios: the influence of CYP2D6 and non-CYP2D6 pathways on biotransformation. J Clin Pharmacol 2002; 42: 24-29.
14. Tanaka E. Gender-related differences in pharmacokinetics and clinical significance. J Clin Pharm Ther 1999; 24: 339-346.
15. May DG, Porter J, Wilkinson GR, Branch RA. Frequency distribution of dapsone N-hydroxylase, a putative probe for P4503A4 activity, in a white population. Clin Pharmacol Ther 1994; 55: 492-500.
16. Garcia-Quetglas E, Azanza JR, Sadaba B, Munoz MJ, Gil I, Campanero MA. Pharmacokinetics of tramadol enantiomers and their respective phase I metabolites in relation to CYP2D6 phenotype. Pharmacol Res 2007; 55: 122-130.